The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
RAS status in circulating-tumor DNA (ctDNA) and outcomes during rechallenge treatments with anti-EGFR antibodies in metastatic colorectal cancer (mCRC).
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Merck; Merck; Merck; Merck; Nippon Kayaku; Nippon Kayaku; Nippon Kayaku; Nippon Kayaku; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Takeda; Takeda; Takeda; Takeda
Research Funding - Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Masato Nakamura
Honoraria - Bayer; Bayer; Bayer; Bayer; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
 
Masahiro Ishizaki
No Relationships to Disclose
 
Masato Kataoka
No Relationships to Disclose
 
Hironaga Satake
Honoraria - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Merck; Merck; Merck; Merck; MSD; MSD; MSD; MSD; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
 
Masaki Kitazono
No Relationships to Disclose
 
Hideyuki Yanagisawa
No Relationships to Disclose
 
Yasuyuki Kawamoto
Honoraria - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda
Research Funding - Japan Agency for Medical Research and Development; Japan Agency for Medical Research and Development; Japan Agency for Medical Research and Development; Japan Agency for Medical Research and Development
 
Hidekazu Kuramochi
No Relationships to Disclose
 
Hisatsugu Ohori
No Relationships to Disclose
 
Michio Nakamura
Honoraria - Asahi Kasei; Asahi Kasei; Asahi Kasei; Asahi Kasei; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Mochida Pharmaceutical Co. Ltd.; Mochida Pharmaceutical Co. Ltd.; Mochida Pharmaceutical Co. Ltd.; Mochida Pharmaceutical Co. Ltd.; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Zeria Pharmaceutical (Inst); Zeria Pharmaceutical (Inst); Zeria Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Fumiyo Maeda
Employment - Sysmex; Sysmex; Sysmex; Sysmex
 
Chihiro Komeno
Employment - Sysmex; Sysmex; Sysmex; Sysmex
 
Masahiro Takeuchi
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Hisamitsu Pharmaceutical; Hisamitsu Pharmaceutical; Kyorin; Kyorin; Modulus Discovery; Modulus Discovery
 
Masashi Fujii
Travel, Accommodations, Expenses - Japan Clinical Cancer Research Organization; Japan Clinical Cancer Research Organization; Japan Clinical Cancer Research Organization; Japan Clinical Cancer Research Organization; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Takayuki Yoshino
Research Funding - Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); PAREXEL International Inc. (Inst); PAREXEL International Inc. (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst)
 
Wataru Ichikawa
Honoraria - Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Merck Serono; Merck Serono; Merck Serono; Merck Serono
Research Funding - Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Shionogi (Inst); Shionogi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Akihito Tsuji
Speakers' Bureau - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda
Research Funding - Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)